Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Clinical trial NCT07027124 · RECRUITING
Trial details
- NCT number
- NCT07027124
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-21
- Primary completion
- 2027-12-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.